» Articles » PMID: 24661019

The Beneficial Effect of Acromegaly Control on Blood Pressure Values in Normotensive Patients

Overview
Specialty Endocrinology
Date 2014 Mar 26
PMID 24661019
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Control of acromegaly may ameliorate blood pressure (BP) in hypertensive (HT) patients. We evaluated the impact of acromegaly control on BP values of normotensive (NT) acromegalics.

Design: Retrospective cohort study.

Patients: Fifty-eight naïve patients with acromegaly (39 F; age range, 30-69 years), including 28 NT and 30 HT subjects, participated in the study.

Measurements: Blood pressure was measured by clinical measurement and 24-h ambulatory monitoring at diagnosis and after 24 months of medical therapy for acromegaly.

Results: Acromegaly was controlled by medical therapy in 15 NT and 17 HT patients at 24 months. In the NT group, systolic (SBP) or diastolic (DBP) BP significantly increased (all P < 0·005) when acromegaly was uncontrolled, but did not change when the disease was controlled. Changes in SBP and DBP were also significantly different between uncontrolled and controlled NT patients. At 24 months, clinical hypertension was detected only in uncontrolled NT patients (46% vs 0%, P < 0·001), whereas ambulatory hypertension was found in 38% of uncontrolled and in 7% of controlled NT subjects (P = 0·035). In the HT group, ambulatory SBP increased in patients with uncontrolled acromegaly (24-h SBP P = 0·046, day SBP P = 0·005, night SBP P = 0·005), whereas ambulatory DBP decreased in subjects with controlled disease (24-h DBP P = 0·008, day DBP P = 0·026).

Conclusions: Control of acromegaly has a beneficial effect on BP regulation either in HT or NT subjects; in the latter, it may prevent progression towards hypertension.

Citing Articles

Advances in Research on the Cardiovascular Complications of Acromegaly.

Yang H, Tan H, Huang H, Li J Front Oncol. 2021; 11:640999.

PMID: 33869029 PMC: 8050332. DOI: 10.3389/fonc.2021.640999.


Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes.

Vila G, Luger A, van der Lely A, Neggers S, Webb S, Biller B Front Endocrinol (Lausanne). 2020; 11:577173.

PMID: 33329385 PMC: 7734123. DOI: 10.3389/fendo.2020.577173.


Editorial: Health-Related Complications of Acromegaly.

Bolanowski M, Boguszewski C, Colao A, Jawiarczyk-Przybylowska A Front Endocrinol (Lausanne). 2020; 11:496.

PMID: 32849286 PMC: 7403215. DOI: 10.3389/fendo.2020.00496.


Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.

Gatto F, Campana C, Cocchiara F, Corica G, Albertelli M, Boschetti M Rev Endocr Metab Disord. 2019; 20(3):365-381.

PMID: 31342434 DOI: 10.1007/s11154-019-09506-y.


CARDIOVASCULAR COMPLICATIONS OF ACROMEGALY.

Mizera L, Elbaum M, Daroszewski J, Bolanowski M Acta Endocrinol (Buchar). 2019; 14(3):365-374.

PMID: 31149285 PMC: 6525769. DOI: 10.4183/aeb.2018.365.